Smartest Doc
The effects of 17β-estradiol plus drospirenone on anthropometric and biochemical measures of adiposity in menopausal women
Archives of Gynecology and Obstetrics, 07/16/2012
Clinical Article
Karakus M et al. - Leptin was significantly higher and GLP–1 was significantly lower in women receiving 17β–estradiol plus drospirenone treatment. GLP–1 levels were significantly lower after the menopause compared to premenopausal levels. Orexin–A and GLP–1 were positively correlated.
Methods- Twenty postmenopausal and 20 premenopausal women were enrolled in a prospective comparative study.
- Postmenopausal women received 1 mg 17β–estradiol plus 2 mg drospirenone daily for 6 months.
- Measurements of body mass index (BMI), waist/hip ratio and plasmatic levels of insulin, glucose, high–density lipoprotein (HDL), low–density lipoprotein (LDL), triglyceride, leptin, adiponectin, orexin–A, glucagon–like peptide–1 (GLP–1) and ghrelin were performed in premenopausal (group 1) and postmenopausal women and in the latter before (group 2a) and after (group 2b) 6 months treatment with 17β–estradiol plus drospirenone.
- No significant changes in BMIs, insulin and glucose were observed between group 1 and 2a; and group 2a and 2b.
- GLP–1 levels were significantly increased in group 1 compared to group 2a (p = 0.035).
- Leptin levels were significantly increased (p = 0.001) and GLP–1 levels were significantly decreased (p = 0.021) in group 2b compared to group 2a.
- HDL was significantly decreased while LDL and triglyceride levels were significantly increased in group 2a compared to group 1. (p = 0.030, p = 0.001, p = 0.020; respectively) LDL was significantly decreased (p = 0.010) in group 2b compared to group 2a. GLP–1 had a positive correlation with orexin–A (p < 0.001, r = 0.520) and negative correlation with leptin (p = 0.008, r = –0.345).
